![](/img/cover-not-exists.png)
275 Cost-effectiveness in Canada of azacitidine for the treatment of higher risk myelodysplastic syndromes and acute myeloid leukemia
D. Zou, N. Risebrough, R. Buckstein, T. Kim, A. LevyVolume:
35
Year:
2011
Language:
english
Pages:
1
DOI:
10.1016/s0145-2126(11)70277-6
File:
PDF, 52 KB
english, 2011